We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+36.12%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$750M
AUM Growth
+$249M
Cap. Flow
+$154M
Cap. Flow %
20.5%
Top 10 Hldgs %
62.56%
Holding
33
New
10
Increased
14
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$32.8M
2
AXSM icon
Axsome Therapeutics
AXSM
+$26M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24.6M
4
INCY icon
Incyte
INCY
+$16M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.1M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$44.1M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$14.9M
3
ARVN icon
Arvinas
ARVN
+$11.3M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$7.01M
5
UTHR icon
United Therapeutics
UTHR
+$5.03M

Sector Composition

Rank Sector Weight
1 Healthcare 94.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSTX
26
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$7.31M 0.97%
+2,070,108
New +$6.85M
VOR icon
27
Vor Biopharma
VOR
$1.21B
$6.78M 0.9%
85,182
+19,967
+31% +$1.96M
MIST icon
28
Milestone Pharmaceuticals
MIST
$146M
$5.83M 0.78%
+634,211
New +$4.81M
CCCC icon
29
C4 Therapeutics
CCCC
$399M
– –
-73,149
Closed -$552K
ENTA icon
30
Enanta Pharmaceuticals
ENTA
$387M
– –
-148,216
Closed -$7.01M
LQDA icon
31
Liquidia Corp
LQDA
$7.86B
– –
-850,961
Closed -$3.71M
GRCL
32
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-783,445
Closed -$4.31M
SRRA
33
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-801,314
Closed -$44.1M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Paradigm Biocapital Advisors held 33 positions worth $750M, up 50% from $502M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Paradigm Biocapital Advisors deployed $154M of net new capital in Q3 2022, opening 10 new positions and adding to 14 existing holdings. Its largest new stake was Biogen: 154,605 shares worth $41.3M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $14.9M trimmed.

  • Paradigm Biocapital Advisors's largest Q3 2022 buy was Biogen: 154,605 shares worth $41.3M.
  • Paradigm Biocapital Advisors added most to Incyte in Q3 2022, an estimated $16M increase.
  • Paradigm Biocapital Advisors's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $14.9M.
  • Paradigm Biocapital Advisors fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $44.1M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 63% of its $750M portfolio in Q3 2022.
  • Paradigm Biocapital Advisors opened 10 new positions and closed 5 in Q3 2022.
  • Paradigm Biocapital Advisors's portfolio value rose 50% quarter-over-quarter to $750M.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.